Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-SP in Refractory Melanoma
NCT07028008Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Oct 2025
- Primary completion
- May 2027
- Modality
- Peptides, Small Molecules
01
Overview
Open-label, single-arm trial of S-1 + cisplatin in melanoma, sponsored by Samsung Medical Center. Primary endpoint: Safety evaluation up to 6 months. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
S-1 + cisplatin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07028008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028008.